Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.

@article{Wade2007EfficacyOP,
  title={Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.},
  author={A Gardiner Wade and Ian Ford Ford and G. Crawford and Alex D. McMahon and Tali Nir and Moshe Laudon and Nava Zisapel},
  journal={Current medical research and opinion},
  year={2007},
  volume={23 10},
  pages={2597-605}
}
OBJECTIVE Melatonin, the hormone produced nocturnally by the pineal gland, serves as a circadian time cue and sleep-anticipating signal in humans. With age, melatonin production declines and the prevalence of sleep disorders, particularly insomnia, increases. The efficacy and safety of a prolonged release melatonin formulation (PR-melatonin; Circadin* 2 mg) were examined in insomnia patients aged 55 years and older. DESIGN Randomised, double blind, placebo-controlled. SETTING Primary care… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

Understanding primary insomnia in older people.

Nursing older people • 2009
View 6 Excerpts
Highly Influenced

Antidepressants for insomnia in adults.

The Cochrane database of systematic reviews • 2018

Similar Papers

Loading similar papers…